Cardiff Oncology (NASDAQ:CRDF) Earns Buy Rating from Analysts at LADENBURG THALM/SH SH

LADENBURG THALM/SH SH assumed coverage on shares of Cardiff Oncology (NASDAQ:CRDF - Free Report) in a report published on Tuesday, Marketbeat reports. The brokerage issued a buy rating and a $19.00 price objective on the stock.

Several other equities analysts also recently commented on CRDF. HC Wainwright boosted their price objective on Cardiff Oncology from $17.00 to $18.00 and gave the company a "buy" rating in a research report on Friday, May 9th. Jefferies Financial Group initiated coverage on Cardiff Oncology in a research report on Tuesday, June 24th. They issued a "hold" rating and a $3.50 price objective on the stock. Finally, William Blair restated an "outperform" rating on shares of Cardiff Oncology in a research report on Wednesday, June 18th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, Cardiff Oncology currently has a consensus rating of "Moderate Buy" and a consensus target price of $11.70.

Cardiff Oncology Stock Up 7.9%

NASDAQ:CRDF traded up $0.29 during mid-day trading on Tuesday, hitting $3.94. 2,122,061 shares of the company traded hands, compared to its average volume of 1,205,931. The stock's fifty day moving average price is $3.20 and its 200-day moving average price is $3.52. Cardiff Oncology has a one year low of $2.01 and a one year high of $5.64. The firm has a market cap of $262.13 million, a price-to-earnings ratio of -4.28 and a beta of 1.52.

Cardiff Oncology (NASDAQ:CRDF - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.01). Cardiff Oncology had a negative net margin of 8,308.50% and a negative return on equity of 76.45%. The business had revenue of $0.11 million during the quarter, compared to analysts' expectations of $0.09 million. Equities analysts predict that Cardiff Oncology will post -0.99 EPS for the current year.

Institutional Investors Weigh In On Cardiff Oncology

Several large investors have recently added to or reduced their stakes in CRDF. Orbimed Advisors LLC bought a new stake in Cardiff Oncology during the fourth quarter worth approximately $6,677,000. Blair William & Co. IL increased its stake in Cardiff Oncology by 521.0% during the first quarter. Blair William & Co. IL now owns 1,751,274 shares of the company's stock worth $5,499,000 after acquiring an additional 1,469,249 shares during the last quarter. Acorn Capital Advisors LLC bought a new stake in Cardiff Oncology during the fourth quarter worth approximately $6,260,000. Adage Capital Partners GP L.L.C. bought a new stake in Cardiff Oncology during the fourth quarter worth approximately $5,609,000. Finally, Nuveen LLC bought a new stake in Cardiff Oncology during the first quarter worth approximately $2,693,000. 16.29% of the stock is owned by institutional investors.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.